Fore Biotherapeutics Inc.

Based in the United States, Fore Biotherapeutics, fka NovellusDx, operates as a clinical-stage targeted oncology therapeutics developer providing plixorafenib, BRAF-altered cancer programs, and precision oncology drug-development capabilities. The company targeted oncology therapies for patients with cancers driven by BRAF alterations. NovellusDx originally operated as a diagnostics company before pivoting to precision oncology, licensing PLX8394 from Daiichi Sankyo’s Plexxikon unit and rebranding as Fore Biotherapeutics in 2021. The company later advanced plixorafenib through the FORTE Phase 2 basket study.

As of July 2026, the company is led by CEO William R. Hinshaw. In July 2026 the company raised USD 67. 4 million Series D-2 extension funding support late-stage development of plixorafenib, deliver topline FORTE CNS tumor data around the end of 2026, pursue a subsequent regulatory submission, and continue development in rare BRAF V600-mutated solid tumors and advanced solid tumors with BRAF fusions.

Based in Philadelphia, United States, Fore Biotherapeutics, fka NovellusDx, provides targeted oncology therapies for patients with cancers driven by BRAF alterations. NovellusDx originally operated as a diagnostics company before pivoting to precision oncology, licensing PLX8394 from Daiichi Sankyo’s Plexxikon unit and rebranding as Fore Biotherapeutics in 2021. The company later advanced plixorafenib through the FORTE Phase 2 basket study. As of July 2026, the company is led by CEO William R.

Hinshaw. Fore Biotherapeutics develops targeted oncology medicines for patients with unaddressed tumor mutations, primarily through its lead candidate, plixorafenib. Plixorafenib is an investigational next-generation BRAF inhibitor designed to inhibit a wide range of BRAF gene alterations beyond earlier-generation BRAF inhibitors. The company is evaluating it in the registration-intended global Phase 2 FORTE trial for recurrent or progressive BRAF V600E primary CNS tumors, rare BRAF V600-mutated solid tumors, and advanced solid tumors with BRAF fusions.

Its work is supported by oncology drug-development, clinical, regulatory, and business-development teams. The company’s revenue model is not publicly detailed, and plixorafenib remains investigational with no disclosed commercial approval. Fore Biotherapeutics’ website and clinical sources show a development-stage biotechnology model focused on advancing licensed or partnered oncology compounds, clinical trials, and business-development collaborations. The company also states that it considers licensing opportunities and invites potential collaboration discussions.

With the recent USD 67. 4 million Series D extension funding raised in July 2026, the company plans to support late-stage development of plixorafenib, deliver topline FORTE CNS tumor data around the end of 2026, pursue a subsequent regulatory submission, and continue development in rare BRAF V600-mutated solid tumors and advanced solid tumors with BRAF fusions.